Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02685605 · ClinicalTrials.gov registry record · Phase 3
Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
A Phase 3 study of Glioblastoma, sponsored by Universitätsmedizin Mannheim.
- Active
- Registry status
- Phase 3
- Development phase
- 314
- Enrollment target
- 19
- Study locations
NCT02685605 is a Phase 3 study of Glioblastoma that is active but no longer recruiting, run by Universitätsmedizin Mannheim. The registered enrollment target is 314 participants, above the 107-participant average among 199 other Glioblastoma trials with a reported enrollment target (193% higher). The trial reports 19 study locations across 6 states.
The verdict
NCT02685605, a Phase 3 study of Glioblastoma, is active but no longer recruiting, sponsored by Universitätsmedizin Mannheim.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 314 participants
- Enrollment target
- 19
- Study locations
Study Summary
INTRAGO II resembles a multicentric, prospective, randomized, 2-arm, open-label clinical phase III trial which tests if the median progression-free survival (PFS) of patients with newly diagnosed glioblastoma multiforme (GBM) can be improved by the addition of intraoperative radiotherapy (IORT) to standard radiochemotherapy.
Conditions Studied
Interventions
- DRUG Temozolomide
- PROCEDURE Standard surgery
- RADIATION Intraoperative radiotherapy
- RADIATION Radiochemotherapy
Study Locations (19)
Other
- Hospital Alemão Oswaldo Cruz - São Paulo
- Beijing Tian Tan Hospital, Capital Medical University - Beijing
- University Hospital Augsburg - Augsburg
- Charité - Universitätsmedizin - Berlin
- St. Georg Hospital - Leipzig
- University Hospital Mannheim - Mannheim
- Technical University of Munich (TUM), Department of Radiation Oncology - Munich
- Klinikum Stuttgart - Stuttgart
- Helios University Hospital Wuppertal - Wuppertal
- Gangnam Severance Hospital, Yonsei University College of Medicine - Seoul
- Catalan Institute of Oncology (ICO) - Barcelona
- Hospital Reina Sofia - Córdoba
- The London Clinic - London
New York
- Long Island Jewish Medical Center, North Shore University Hospital - Lake Success
- Lenox Hill Hospital, Hofstra Northwell School of Medicine - New York
Arizona
- Barrow Neurological Institute (SJHMC) - Phoenix
Illinois
- Stritch School of Medicine Loyola University - Maywood
West Virginia
- West Virginia University - Morgantown
Quebec
- Montreal Neurological Institute and Hospital - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2016-12-09 |
| Est. Completion | 2026-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02685605
The ClinicalTrials.gov registry entry for NCT02685605 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 314 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 107-participant average among 199 other Glioblastoma trials with a reported enrollment target (193% higher). The listed sponsor is Universitätsmedizin Mannheim, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 4 interventions - of which Temozolomide is the first listed.
NCT02685605 reports 19 study locations spanning 6 distinct geographic areas - top geographies include Other, New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT02685605 about?
NCT02685605 is a clinical study titled "Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme". INTRAGO II resembles a multicentric, prospective, randomized, 2-arm, open-label clinical phase III trial which tests if the median progression-free survival (PFS) of patients with newly diagnosed glioblastoma multiforme (GBM) can be improved by the addition of intraoperative radiotherapy (IORT) to s...
What is the current status of trial NCT02685605?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 314 participants. The study started on 2016-12-09. Estimated completion is 2026-06.
What conditions does trial NCT02685605 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT02685605?
The interventions under investigation include: Temozolomide (DRUG), Standard surgery (PROCEDURE), Intraoperative radiotherapy (RADIATION), Radiochemotherapy (RADIATION).
Who is sponsoring clinical trial NCT02685605?
This trial is sponsored by Universitätsmedizin Mannheim, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02685605 being conducted?
This trial has 19 study locations across Arizona, Illinois, New York, West Virginia, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
RECRUITING · Phase 3
-
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
RECRUITING · Phase 3
-
Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients
RECRUITING · Phase 3
-
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
RECRUITING · Phase 3
-
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
RECRUITING · Phase 3
-
Tofacitinib in Recurrent GBM Patients
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.